The therapeutic properties of Ginseng have been known as popular Chinese midecine since time immemorial. It has been used in Korea, China, Tibet, Indonesia and India for thousands of years under various presentations, such as tes, tinctures, wines, pills, and unguents for the prevention of aging, tireness, headaches, amnesia, tuberculosis, diabetes, illness of the liver, heart, kidneys, nervous system etc. The main effective component of Ginseng has recently been considered to be saponins according to the chemical studies by Shibata's group and the pharmacological studies by Takagi et al., and also through the studies of Brekhman. The purpose of this study is to evaluate the response of topically applied Ginseng total saponin against inflammation. To induce the inflammation of skin the backs of 20 volunteers were treated with 10% sodium lauryl sulfate solution under occlusion for one hour. After removal of sodium lauryl sulfate. Gineseng total saponin ointment in various concentrations(2.5, 5, 10%) is topically applied under occlusion for 48 hours. Erythema on the areas treated with Ginseng total saponin ointment was significantly reduced than the control area. It is suggested that Ginseng total saponin has an anti-inflammatory effect on the inflammation of skin induced by sodium lauryl sulfate.
Aging ; Amnesia ; Asian Continental Ancestry Group ; China ; Erythema ; Headache ; Heart ; Humans* ; India ; Indonesia ; Inflammation ; Kidney ; Korea ; Liver ; Nervous System ; Ointments ; Panax* ; Saponins* ; Skin* ; Sodium Dodecyl Sulfate ; Tibet ; Tuberculosis ; Volunteers ; Wine

No abstract available.

No abstract available.

OBJECTIVE: The purpose of this study was to investigate possible menopause related changes in circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and their relationship with insulin-like growth factor 1 (IGF-1) plasma levels, osteocalcin(Ost) and urinary deoxypyridinoline(Dpd) in either surgical menopause or natural menopause, METHOD: Seventy-two postmenopausal women (surgical menopause 48, natural menopause 24) were invited to participate in this study. In all subjects plasma IGF-1 and IGFBP-3 levels were measSURED by radioimmunoassay and Ost and Dpd were measured by enzyme linked immunosorbent assay(ELISA). RESULTS: No difference was found between mean IGFBP-3 plasma levels in the two groups studied(3,522 +/- 926 vs 3,854 +/- 569 ng/ml), while mean IGF-1 levels were significantly lower in natural menopause as compared with surgical menopause (natural 126 +/- 44 vs surgical 163 +/- 66 ng/ml, p=0.007). No difference was found between mean Ost levels in the two groups studied (natural menopause 8.0 +/- 2.9 vs surgical menopause 8,9 +/- 2.1 ng/ml, p=0.113) and mean Dpd levels in the two studied (natural menopause 6.8 +/- 2.3 vs surgical menopause 7.8 +/- 3.4 mM, p=0.213). CONCLUSION: IGF-1 was significantly lower in natural menopause as compared with surgical menopause, but no significant difference was found in IGFBP-3, Ost, and Dpd levels
Biomarkers* ; Carrier Proteins* ; Female ; Humans ; Insulin* ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor Binding Proteins* ; Insulin-Like Growth Factor I ; Menopause* ; Osteocalcin* ; Plasma ; Radioimmunoassay

BACKGROUND: It is well known that excessive thyroid hormone in the body is associated with bone loss. However, the mechanism by which thyroid hormone affects bone cell metabolism remains unclear. It has been shown that thyroid hormones stimulate osteoclastic bone resorption indirectly via some unknown mediators secreted by osteoblasts, This study was undertaken to determine if interleukin-6 (IL-6) or interleukin-11 (IL-l1) could be the mediator (s) of thyroid hormone-induced bone loss. METHODS: We treated primary cultured human bone rnarrow stromal cells with 3,5,3-triiodo-thyronine (T) and measured basal and interleukin-l (IL-1)-stimulated IL-6/IL-ll production. We also investigated the possible modulating effect of 17B-estradiol (17B-E2.) on thyroid hormone action. RESULTS: T3 at 10 (-12) ~ 10 (-8) M concentration, significantly increased the basal IL-6 production in a dose-dependent manner, and also potentiated the stimulatory effect of IL-1 on IL-6 production. However, T failed to elicit a detectable effect on basal or IL-1-stimulated IL-11 production. Treat#ment with l7B-E2. inhibited IL-1-stimulated IL-6 production, but the effects of T3 on IL-6 production were not affected by 17/B-E. CONCLUSION: These results suggest that thyroid hormone may increase bone resorption by increasing basal IL-6 production and potentiating IL-1-induced IL-6 production from osteoblast-lineage cells, and these effects were independent of estrogen status.
Bone Marrow* ; Bone Resorption ; Estradiol ; Estrogens ; Humans* ; Interleukin-1 ; Interleukin-11* ; Interleukin-6* ; Mesenchymal Stromal Cells* ; Metabolism ; Osteoblasts ; Osteoclasts ; Osteoporosis ; Stromal Cells ; Thyroid Gland* ; Thyroid Hormones

No abstract available.
Polycystic Kidney Diseases*

No abstract available.
Osteoarthritis*

No abstract available.
Endometrial Stromal Tumors* ; Lung* ; Neoplasm Metastasis* ; Uterus*

No abstract available.
Pierre Robin Syndrome*

No abstract available.
Adenocarcinoma, Clear Cell* ; Vagina*